Welcome to our dedicated page for PEAR news (Ticker: PEAR), a resource for investors and traders seeking the latest updates and insights on PEAR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect PEAR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of PEAR's position in the market.
Pear Therapeutics, Inc. (Nasdaq: PEAR) will host a conference call and webcast at 4:30 p.m. ET on March 28, 2022, to discuss its financial results for the fourth quarter and full year of 2021. Investors can access the call via phone at (877) 814-6630 for U.S. callers or (409) 216-0625 for international participants using passcode 8586341. A live webcast will also be available on the company's website, with a replay accessible approximately two hours after the call.
Pear Therapeutics, Inc. (Nasdaq: PEAR), a leader in software-based medicines, will participate in the virtual 42nd Annual Cowen Healthcare Conference on March 9. Dr. Corey McCann, President and CEO, will engage in an analyst-led fireside chat at 2:50 p.m. ET. Investors can access the live audio webcast here, and a replay will be available for 30 days post-event on Pear's website. Pear is known for developing prescription digital therapeutics, including FDA-approved products for substance use disorders and chronic insomnia.
Pear Therapeutics (Nasdaq: PEAR) has announced that the Centers for Medicare & Medicaid Services (CMS) established a new Level II HCPCS code (A9291) for prescription digital therapeutics (PDTs) including their products reSET®, reSET-O®, and Somryst®. This code will facilitate reimbursement for these FDA-cleared PDTs aimed at treating substance use disorder, opioid use disorder, and chronic insomnia. The decision, effective April 1, 2022, marks a significant milestone for access and reimbursement in the PDT category.
Pear Therapeutics, Inc. (Nasdaq: PEAR) announced its participation in Citi’s 2022 Virtual Healthcare Conference on February 24. President and CEO Corey McCann will engage in an analyst-led fireside chat at 2:00 p.m. ET. Investors can access the live audio webcast here and on Pear's website. Pear is a pioneer in prescription digital therapeutics (PDTs), aiming to transform patient care with clinically validated software-based medicines. The company has received FDA marketing authorizations for three PDTs, including reSET® and Somryst®.
Pear Therapeutics (NASDAQ: PEAR) has announced the launch of Spanish-language versions of reSET® and reSET-O®, the first FDA-authorized prescription digital therapeutics for substance use disorder (SUD) and opioid use disorder (OUD). This initiative aims to address significant healthcare disparities faced by the Hispanic community, where research indicates that 90% of those with SUD do not receive adequate treatment. The addition of Spanish-language resources enhances access and support for underserved populations, promoting better health equity and treatment outcomes.
The state of Michigan will fund access to Pear Therapeutics' prescription digital therapeutics (PDTs), reSET® and reSET-O®, for treating substance use disorders. With opioid overdose deaths in Michigan increasing ten-fold since 2000, these PDTs aim to enhance treatment accessibility. Pear's Chief Commercial Officer commended Michigan's leadership for addressing the overdose epidemic. reSET and reSET-O have shown promise in improving health outcomes and reducing healthcare resource utilization, substantiated by clinical trials.
Pear Therapeutics, Inc. (NASDAQ: PEAR) announced participation in the 9th Annual BTIG MedTech, Digital Health, Life Science & Diagnostics Conference from February 15-17. CEO Corey McCann will engage in a fireside chat on February 16 at 2:00 PM ET. The conference is exclusive to BTIG clients.
Pear Therapeutics is a leader in developing software-based medicines, known as prescription digital therapeutics (PDTs), with three products approved by the FDA targeting substance use disorder and chronic insomnia.
Pear Therapeutics (Nasdaq: PEAR) announced a value-based agreement with the Oklahoma Health Care Authority to provide access to its prescription digital therapeutics, reSET® and reSET-O®, effective January 1, 2022. These products aim to address substance and opioid use disorders in Oklahoma Medicaid enrollees, enhancing treatment access for rural populations. The collaboration leverages outcomes-based benchmarks to improve healthcare for SoonerCare members, potentially leading to reduced healthcare costs.
Pear Therapeutics (NASDAQ: PEAR) announced strong 2021 commercial performance metrics, meeting public guidance in prescriptions, fulfillment rate, and covered lives. Over 550 providers issued more than 14,000 prescriptions for its products reSET®, reSET-O®, and Somryst®. The company also expanded market access to over 31.7 million covered lives. Pear reaffirms its 2022 guidance, projecting 50,000-60,000 prescriptions and $22 million in revenue. With FDA Breakthrough Device Designation for reSET-A™, Pear aims to enhance its addiction treatment portfolio.
Pear Therapeutics (NASDAQ: PEAR) has announced a partnership with Point32Health to enhance access to its FDA-authorized digital therapeutics for members suffering from substance use disorder (SUD) and opioid use disorder (OUD). This collaboration aims to support recovery through Pear’s prescription digital therapeutics (PDTs), including reSET and reSET-O, which have demonstrated efficacy in clinical trials. The partnership responds to rising drug overdose deaths exacerbated by the pandemic, providing innovative treatment options that reduce stigma and improve health outcomes for patients.
